EGFR gene mutation positive non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Kyoto prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients has been confirmed histologically or cytologically non-small cell lung cancer. 2. Patients planning to treat Afacinib or first generation EGFR-TKI. 3. Patients where tissues can be harvested for this study prior to afatinib or first generation EGFR-TKI treatment and resistance. 4. The PS of ECOG is 0 or 1. 5. There are no major obstacles in major organs (bone marrow, heart, lung, liver, kidney etc.). 6. Patient that is expected to survive for at least 3 months. 7. Patients in which consent has been obtained in the document for this study. 8. The age at registration is 20 years or older. 9. Participants in "prospective observational research (LC-SCRUM)" to clarify the clinicopathological and molecular biological characteristics of low-frequency genetic change positive lung cancer such as RET fusion gene.
Exclusion criteria
Exclusion criteria: Patients otherwise considered unsuitable to participate in this study by investigators at study sites
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Potential predictive anomalies in genes and proteins that can be candidates for the resistance factor of afatinib | — |
Countries
Japan
Contacts
Public ContactKeiko Tanimura
Kyoto prefectural University of Medicine Department of Respiratory Medicine
Outcome results
None listed